<SEC-DOCUMENT>0001144204-18-047697.txt : 20180904
<SEC-HEADER>0001144204-18-047697.hdr.sgml : 20180904
<ACCEPTANCE-DATETIME>20180904080033
ACCESSION NUMBER:		0001144204-18-047697
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180904
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180904
DATE AS OF CHANGE:		20180904

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TITAN PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000910267
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943171940
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13341
		FILM NUMBER:		181051276

	BUSINESS ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6502444990

	MAIL ADDRESS:	
		STREET 1:		400 OYSTER POINT BLVD
		STREET 2:		SUITE 505
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv502214_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C.&nbsp; 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event
Reported): September 4, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Titan
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Delaware</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%; text-align: center"><B>001-13341</b></TD>
    <TD STYLE="width: 50%; text-align: center"><B>94-3171940</b></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center">(Commission File Number)</TD>
    <TD STYLE="text-align: center">(IRS Employer
Identification No.)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>400 Oyster Point Blvd., Suite 505, South
San Francisco, CA 94080</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 75%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><BR>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>650-244-4990</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 75%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant's telephone number including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 75%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant's former name or former address,
if changed since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12(b) under
the Exchange Act (17 CFR 240.14a-12(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><B>Item 8.01.</B></TD><TD><B>Other Events.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 4, 2018, Titan Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
announced the initiation of a pilot program in collaboration with the Nevada Center for Behavioral Health to evaluate a medication-assisted
treatment (MAT) program utilizing Probuphine&reg; for Opioid Use Disorder (OUD) patients within the State of Nevada criminal justice
system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the press release issued by the Company is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in; text-align: left"><B>Item 9.01.</B></TD><TD STYLE="text-align: justify"><B>Financial
                                         Statements and Exhibits.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; padding: 0; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit No. </FONT></TD>
    <TD STYLE="padding: 0; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; font-size: 10pt"><A HREF="tv502214_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; font-size: 10pt"><A HREF="tv502214_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated September 4, 2018.</FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">TITAN PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U STYLE="text-decoration: none">/s/ Sunil Bhonsle&#9;</u></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Name:&nbsp;</TD>
    <TD>Sunil Bhonsle</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer and President</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Dated: September 4, 2018</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><BR>
<BR> &#9;<BR>
 &#9;<BR>
 &#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 283.5pt; text-indent: -283.5pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv502214_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 62.25pt; width: 167.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TITAN AND THE NEVADA CENTER FOR BEHAVIORAL
HEALTH COLLABORATE TO EVALUATE PROBUPHINE&reg; TREAMENT OF OUD PATIENTS WITHIN THE STATE OF NEVADA CRIMINAL JUSTICE SYSTEM </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SOUTH SAN FRANCISCO, CA &ndash; September
4, 2018 &ndash; Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of
select chronic diseases utilizing its ProNeura&trade; long-term, continuous drug delivery technology, today announced the initation
of a pilot program in collaboration with the Nevada Center for Behavioral Health (NCBH) to evaluate a medication-assisted treatment
(MAT) program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients within the State of Nevada criminal
justice system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pilot program was initiated with Titan&rsquo;s
training and certification of seven Health Care Providers within the Nevada criminal justice system on the Probuphine Risk Evaluation
and Mitigation Strategy (REMS) program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;There is increasing recognition
that the rate of recidivism among inmates with OUD is very high, as is the incidence of overdose and death for recently released
inmates who have &lsquo;detoxed&rsquo; without the benefit of MAT while incarcerated,&rdquo; said Titan&rsquo;s Chief Scientific
Officer, Dr. Kate DeVarney. &ldquo;In addition to this project, our plan is to establish similar pilots with other select criminal
justice programs, with the goal of generating meaningful data that potentially supports the use of Probuphine in this population.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This pilot program is being supported through
an Opioid State Targeted Response (STR) Integrated Opioid Treatment and Recovery Centers (IOTRC) grant awarded to the Center for
Behavioral Health in May 2018. Nevada&rsquo;s STR is funded by a federal grant accepted by the State of Nevada as part of the 21<SUP>st</SUP>
Century Cures Act, which was passed by the U.S. Congress in 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;For many people with OUD, the most
effective treatment is the combination of counseling and MAT with medications such as buprenorphine,&rdquo; commented Dr. Stephanie
Woodard, Senior Advisor on Behavioral Health for the State of Nevada Department of Health and Human Services, Division of Public
and Behavioral Health Bureau of Behavioral Health, Prevention, and Wellness. &ldquo;To-date, that treatment regimen has not been
made widely available to patients within the State of Nevada criminal justice system. We look forward to seeing the results of
this pilot MAT program for OUD patients, both inside and, ultimately, outside of Nevada&rsquo;s prison and jail systems.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About OUD Within the Criminal Justice
System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is estimated that of the 2.3 million
people currently confined in U.S. correctional facilities, approximately 25% suffer from OUD. Currently, less than 1% of U.S. prisons
and jails allow access to medication for OUD due largely to the risk of misuse and diversion of sublingual formulations. However,
new research published by <I>JAMA Psychiatry</I> has demonstrated benefits of buprenorphine during incarceration and upon release.
In Rhode Island, a recent study found that opioid overdose deaths dropped by nearly 2/3 when MAT was provided to all state inmates.
A few criminal justice programs have begun to utilize medications in order to address jail overcrowding and recidivism related
to OUD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Probuphine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Probuphine is the only subdermal implant
designed to deliver buprenorphine continuously for six months following a single treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Probuphine was developed using ProNeura&trade;,
the continuous drug delivery system developed by Titan that consists of a small, solid implant made from a mixture of ethylene-vinyl
acetate and a drug substance. The resulting construct is a solid matrix that is placed subdermally, normally in the upper arm in
an outpatient office procedure and removed in a similar manner at the end of the treatment period. The U.S. Food and Drug Administration
(FDA) approved Probuphine in May 2016, and it is the first and only buprenorphine implant available for the maintenance treatment
of opioid addiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Please see Full Prescribing Information,
including <B>BOXED WARNING</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Titan Pharmaceuticals</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Titan Pharmaceuticals, Inc. (NASDAQ:TTNP),
based in South San Francisco, CA, is developing proprietary therapeutics primarily for the treatment of select chronic diseases.
The company's lead product is Probuphine<SUP>&reg;</SUP>, a novel and long-acting formulation of buprenorphine for the long-term
maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura&trade;, which
is capable of delivering sustained, consistent levels of medication for three months or longer. Approved by the FDA in May 2016,
Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels
of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing
products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock
blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit
www.titanpharm.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Forward-Looking Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This press release may contain &quot;forward-looking
statements&quot; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other
statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's
current expectations include those risks and uncertainties relating to the commercialization of Probuphine, the regulatory approval
process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and
strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based, except as required by law. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CONTACTS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sunil Bhonsle,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">President &amp; CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(650) 244-4990</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stephen Kilmer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(650) 989-2215</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">skilmer@titanpharm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red"><B>&nbsp;&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #! @4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYC_^)H_X6)XK_P"@LW_?F/\ ^)H]H@_U?Q/\T?Q_R/?Z*\ _X6)XK_Z"S?\
M?F/_ .)H_P"%B>*_^@LW_?F/_P")H]H@_P!7\3_-'\?\CW^BO /^%B>*_P#H
M+-_WYC_^)KT+X>WGB76E?4]5OW>Q&4BC,2+YC=SD#.!_/Z4U--V1AB<HJX:F
MZE22M\_\CO:***L\D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** *=[JNGZ:4%]?6]L7SL\Z4)NQUQGZU5_P"$IT#_ *#>G_\
M@2G^->??&3_7Z/\ [LO\TKR^LI5&G8^AP62T\10C5E-IOT[GTC_PE.@?]!O3
M_P#P)3_&C_A*= _Z#>G_ /@2G^-?-U%+VK.K_5VE_._N1](_\)3H'_0;T_\
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M4[NY[N#SKZM1C2Y+V\_^ ?+.UO[I_*C:W]T_E7U-12]EYG3_ *Q?]._Q_P"
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MV^+7_(3TW_KBW_H5>DZ+_P @+3_^O:/_ -!% %ZBBB@ HHHH **** "BBB@
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M10 4444 %<;\3O\ D3V_Z[I_6NRKC?B=_P B>W_7=/ZT 4?A/_R [[_KY_\
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MJW.EQ74;WULB230 _,BM]TGZXJY0 45DZSXGT/P\8AK&JVMD903&)Y I;'7
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M(50,D]31Y,7G>=Y:>;MV[]HW8ZXSZ4^B@ IB0Q1.[QQ(C2'+E5 +'U/K3Z*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
